Eli Lilly acquires gene-editing biotech Verve Therapeutics for $1.3 billion, expanding its pipeline in cardiovascular therapies.
Gamblers' abuse of tennis players, including death threats, highlights the need for stronger industry and social media action to protect athletes' safety.
Eli Lilly acquires gene-editing biotech Verve Therapeutics for $1.3 billion, expanding its pipeline in cardiovascular therapies.
Gamblers' abuse of tennis players, including death threats, highlights the need for stronger industry and social media action to protect athletes' safety.